Aspirin Use Improves Survival in elderly with Bladder or Breast Cancer: JAMA
Aspirin is recommended for the prevention of cardiovascular diseases events in the past decades and is one of the most commonly used drugs worldwide. A recent study suggests that any aspirin use and aspirin use at least 3 times/week was associated with improved bladder and breast cancer survival. The study findings were published in the journal JAMA Network Open on January 15, 2021.
The aspirin use, nonselectively inhibits cyclooxygenase, thus suppressing inflammation, it stands to reason that long-term aspirin use may affect cancer initiation. Recent large-scale evaluations have indicated aberrant immune cell activity in several tumor types, including bladder, breast, gastric, and uterine tumors, providing a prime target for aspirin activity. Furthermore, aspirin use has been demonstrated to affect survival after a cancer diagnosis, although the data remain mixed. Many studies have evaluated the long-term benefits of aspirin use; however, the association of aspirin use with cancer incidence and survival in older individuals remains uncertain. Additional population-based evidence of this association is necessary to better understand any possible protective effects of aspirin in older adults. Therefore, researchers of the National Cancer Institute, Maryland conducted a study to investigate the association of aspirin use with risk of developing new cancers and site-specific cancer-associated survival in bladder, breast, esophageal, gastric, pancreatic, and uterine cancers.
It was a post hoc analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. Researchers included a total of 1,39,896 participants who were aged 65 years or older at baseline (1993-2001) or reached age 65 during follow-up. They analyzed the data from January to June 2020. The major outcome assessed was the incidence of and survival from the investigated cancer types. They used Cox proportional hazards regression model to calculate the Univariable and multivariable hazard ratios (HRs) and 95% Confidence intervals by adjusting for covariates.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.